HWI Pharma & Policy Digest

Why it matters: With no functioning ACIP, the federal vaccine-recommendation pipeline is frozen — no new votes, no schedule changes, and the Dec 2025 hep B birth-dose rollback remains the last major action. Judge Brian Murphy's March 16 stay still holds the committee below quorum despite two charter rewrites (April, May) and a late-May Executive Order; watch the AAP v. Kennedy docket (next hearing referenced for August). Because ACIP recommendations drive ACA first-dollar coverage and VFC purchasing, commercial planning for pediatric and adult vaccines now hinges on litigation timing and state-level divergence, not a federal calendar.

Why it matters: Standard approval for adults 50–64, accelerated for 65+ with post-marketing studies. VRBPAC is filling the vaccine-guidance vacuum on the FDA side even as the CDC/ACIP side stays frozen — the regulatory action is bifurcating. For manufacturers, the fastest current path to a positive federal signal now runs through FDA advisory committees, not ACIP (VRBPAC also locked the XFG COVID strain on May 28).

Why it matters: Maryland gives its health secretary authority to recommend vaccines independent of ACIP and locks in coverage for the ACIP-recommended slate as of Dec 31, 2024 — protecting revenue against federal rollbacks. Minnesota cuts the other way, barring minors from HPV or hep B vaccines without parental consent, which will depress adolescent Gardasil 9 uptake. Together they signal a 50-state patchwork of recommending bodies — raising market-access complexity for every new launch and splitting adolescent access along political lines.

Why it matters: Maryland is now the second state (after Colorado) actively setting UPLs, moving fast through a diabetes / GLP-1 cluster (Jardiance, Farxiga, Ozempic, Trulicity) starting with state / local government plans. This puts high-revenue metabolic brands from Novo, AstraZeneca, Boehringer, and Lilly directly in the crosshairs of state price-setting, and the Medicare-MFP-anchored methodology signals PDABs will import federal negotiated prices as their benchmark.

Why it matters: The gap between PDAB authority and PDAB results remains wide: Colorado's first UPL (Enbrel) doesn't bite until January 2027 and faces litigation, and newer boards are bogged down building frameworks and staffing. The near-term commercial threat is concentrated (CO, MD) rather than broad — buying time to shape the methodology fights — but the trajectory is clearly toward binding limits.

Why it matters: WA joins the wave of state 340B "protection" laws barring manufacturers from restricting contract-pharmacy distribution — penalties up to $5,000/day per violation. The live injunction fight, landing the same week the law went effective, makes WA a bellwether for whether states can override manufacturers' contract-pharmacy restrictions, a multibillion-dollar question for every 340B-exposed brand.

Why it matters: The federal government siding with manufacturers against a state 340B law is a notable signal that could tilt several circuit fights. Combined with the 4th Circuit's March 31 ruling blocking West Virginia's law, a circuit split is now teed up for possible SCOTUS review — manufacturers are winning in the 4th while other circuits have upheld state laws, so 340B exposure will vary sharply by geography until the Supreme Court resolves it.

Why it matters: The federal PBM-reform architecture is now concrete: CAA 2026 (enacted Feb 3) mandates 100% rebate pass-through and independent audits, while the DOL rule forces granular, drug-level pricing transparency to plan fiduciaries. For manufacturers, mandated pass-through plus transparency erodes the rebate-driven formulary economics that have shielded high-list-price brands — accelerating the shift toward net-price competition and pressuring gross-to-net strategies.

Why it matters: For the first time CMS is pulling prescription drugs into its electronic prior-authorization interoperability framework and tightening decision timeframes. This should speed access and reduce administrative friction for specialty and biologic products where PA delays currently suppress starts and drive abandonment — a modest tailwind for PA-heavy therapies, though real impact waits on the 2027 effective date and final rule.

Why it matters: MFN is reshaping the launch and pricing playbook — manufacturers are being pressed to extend MFN prices to Medicaid, guarantee MFN on new launches across Medicare / Medicaid / commercial, and build direct-to-consumer channels. DTC GLP-1 pricing directly reprices the highest-revenue category in pharma and normalizes a cash-pay MFN channel that could bleed into other classes; the White House projects $64.3B in Medicaid MFN savings over 10 years — durable pressure on US net prices.

Why it matters: Cycle 3 (list published Jan 27, 2026) is the first to include Part B physician-administered drugs, expanding negotiation into the buy-and-bill world and raising the stakes for oncology and specialty injectables. The June 1 offer exchange kicks off the substantive negotiation phase for 2028 prices — and PDABs increasingly anchor their own UPLs to these federal MFP figures.